Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine

In focus with: Steve Reed, CEO, co-founder, HDT Bio

HDT Bio’s vision: mRNA has already proved its worth in the fight against infectious diseases. Now Seattle-based HDT Bio is working on a next-generation RNA technology to fight cancer and infectious disease that it said is cheaper, easier to manufacture and transport and even safer than current mRNA vaccines.